XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Apr. 01, 2023
Mar. 26, 2022
Cash flows from operating activities:    
Net loss $ (2,628,555) $ (1,372,664)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 224,574 267,590
Accretion of premium or discount on marketable debt securities 128
Stock-based compensation 194,190 656,073
Loss on sale of property and plant 202,671
Gain on investment transactions (4,700,000)
Income taxes 39,105 35,836
Foreign currency gains (118,697) (16,351)
Change in allowance for credit losses 495,000 (26,281)
Write-off of excess inventory 292,405 588,175
Changes in other non-cash items 200,000 453,262
Changes in assets and liabilities:    
Accounts receivable (420,919) 5,777,308
Contract assets and unbilled receivables 934,759 (252,809)
Inventory (665,589) (1,156,461)
Prepaid expenses, other current assets and other assets (525,705) (314,361)
Accounts payable and accrued expenses (1,983,304) (107,657)
Contract liabilities and billings in excess of revenue earned (211,815) (2,317,122)
Net cash used in operating activities (4,174,551) (2,282,663)
Cash flows from investing activities:    
Capital expenditures (216,618) (524,368)
Purchases of marketable debt securities (17,624,779) (3,000,030)
Proceeds from sale of marketable debt securities 1,000,000 1,000,000
Other assets 1,000
Net cash used in investing activities (16,840,397) (2,524,398)
Cash flows from financing activities:    
Issuance of common stock and pre-funded warrants, net of costs 21,335,000
Settlements of restricted stock for tax withholding obligations (95,613)
Net cash provided by (used in) financing activities 21,335,000 (95,613)
Effect of exchange rate changes on cash 4,216 (17,765)
Net increase (decrease) in cash and cash equivalents 324,268 (4,920,439)
Cash and cash equivalents:    
Beginning of period 8,258,878 26,787,931
End of period $ 8,583,146 $ 21,867,492